The use of metabolomics profiling to understand metabolism under different 20 physiological states has increased in recent years, which created the need for robust analytical 21 platforms. Here, we present a validated method for targeted and semi-quantitative analysis of 102 22 polar metabolites that covers major metabolic pathways from 24 classes in a single 17.5-min assay.
All metabolites were extracted, separated with HILIC chromatography (Acquity BEH amide, 2.1 148 X 100 mm, 1.7µ), and analyzed with a Waters Xevo TQ-S mass spectrometer using our previously 149 published protocol [11] . The protocol for tissues and adherent cells was optimized for better recovery 150 and chromatography and to cover a wide range of tissue and cell types with a single protocol. For 151 tissue sample extractions, 90/10% ACN/H2O + 1% formic acid was used instead of 80/20% ACN/H2O 152 + 1% formic acid during the second step of extraction. Additionally, during cell pellet sample 153 extraction, 80/20% ACN/H2O+1% formic acid was replaced with 90/10% ACN/H2O + 1% formic acid.
154
After optimization, we used the tissues protocol for analysis of various biological matrices, such as 155 heart, liver, placenta, brain, muscles, spleen, C. elegans, Drosophila larvae, dental carries, dried blood Validation of the method was performed to verify various parameters and the reliability of the 162 developed method for analysis of a large number of samples. The method was validated according 163 to EMA guidelines for bioanalytical method validation in terms of selectivity, specificity, linearity, 164 accuracy, precision, extraction recovery, matrix effect, and stability [38] . In addition, we used pooled 165 healthy human serum samples as internal quality control (QC) samples in all studies to correct signal 166 drift during sample runs and to improve confidence in the statistical data. QC samples at high, 167 medium and low (for serum) or high and low concentration levels (for tissues) were prepared by 168 spiking a mixed standard solution in their respective homogenized biological matrices to perform all 169 the method validation experiments. We performed validation for commonly used biological samples 170 in metabolomics analyses, such as biofluid (serum), tissue (liver, brain and spleen), and cell samples.
171
An aqueous calibration curve was used to calculate the concentration values during the method 172 validation. The instrument performance for response reproducibility and sensitivity was always 173 verified by six consecutive injections of medium concentration solution at the start of any experiment. To assess the linearity, accuracy, and precision, six replicates of spiked QC samples at high, 182 medium, and low concentrations along with calibration curve were injected on three separate days.
183
Calibration curve standards of 11 points were prepared via serial dilution. The curve was plotted by 184 using the peak area response ratios (standard/labeled standard) versus the concentrations of the 185 individual metabolites. The calibration curve was constructed using the regression equations (linear 186 and quadratic) by applying appropriate weighing factor and by transforming the axis (both 187 instrument response and theoretical concentration) into logarithmic or square root function. The 
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Wet extract, freeze-thaw, and stock solution stability for all metabolites were determined to 202 check the integrity of the analytes in solvents and in QC samples at different conditions. To determine 203 the wet extract stability, six replicates of extracted QC samples were kept in the auto-sampler at 5°C.
204
The same samples in the same sequence were reinjected with freshly extracted QC samples and the 205 results were compared.
206
Freeze-thaw stability was evaluated up to three cycles by freezing and thawing the spiked QC 207 samples stored at -80°C and comparing the concentrations against the freshly thawed and spiked QC 208 samples.
209
Long-term stock solution stability for metabolite stock solutions and intermediate solutions were 210 checked by comparing the mean peak area of freshly prepared solutions with stored solutions at 4°C.
211
All stability experiments were performed with six replicates of QCs. To further evaluate the robustness and performance of our method, we performed a cross-236 platform comparison using two completely different analytical platforms: (1) the commercially 237 available AbsoluteIDQ p180 targeted metabolomics assay kit using LC-MS/MS and (2) a nuclear 238 magnetic resonance (NMR) platform. We sent our internal QC samples to the BIOCRATES Life
239
Sciences AG (Innsbruck, Austria) (N=3 replicates) and to the NMR Metabolomics Laboratory, School 240 of Pharmacy, University of Eastern Finland (Kuopio, Finland) (N=3 replicates). Our QC samples were 241 extracted and analyzed as described previously for the AbsoluteIDQ p180 kit [40] and for the NMR 242 analysis of small molecules [41] . We compared these results with the results obtained from our 243 method (N=4-5 replicates). 
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The preprocessing steps included the following:
Molecular weight normalization, in which the ppb values are normalized by the molecular 264 weight of each compound, thereby converting the data from ppb units to µmoles.
265
(ii) Process efficiency correction for the semi-quantification of metabolites without internal 266 standards.
267
(iii) Normalization using dilution factor for specific sample type if dilution was needed.
268
(iv) Cell number normalization (for cell samples) to convert the concentration values per million 269 cells.
270
(v) Calculation of mean, standard deviation, and relative standard deviation (RSD) of molecular 271 concentrations (resulting from the previous steps) for each phenotypic group.
272
(vi) Outlier detection in each phenotypic group; if the concentration value of a compound in a 273 sample is more than one or two standard deviation (SD) away from the mean of the 274 phenotypic group, then it is marked as an outlier in the Excel data set in two different colors. The primary objective of this work was to optimize and validate our previously published 283 protocol for different types of biological matrices. For tissue samples (placenta, liver, heart, brain, 284 spleen, and muscles), the sample volumes of the tissues and extraction solvent volumes were 285 optimized to fit the concentrations of most of the metabolites within the linearity of calibration curve 286 for reliable results. We observed that most of the metabolites can be semi-quantified within the 287 calibration curve range with 20±5mg of sample weight.
288
Furthermore, we optimized the protocol with extraction solvent for tissues and adherent cells.
289
Some of the metabolites (in particular inositol, GABA, asymmetric dimethylarginine, symmetric 290 dimethylarginine, spermidine, ribose-5-phosphate, and orotic acid) had poor separation and 291 irreproducible chromatography. Interference of isobaric compounds with other metabolites was also 292 observed due to poor separation. Thus, different compositions of the extraction solvent were assessed 293 to achieve the acceptable chromatography. We observed that modification of acetonitrile content 294 from 80% to 90% and applying longer equilibration time for the HILIC column yielded acceptable 295 chromatography and also good separation for most of the metabolites.
296
We also optimized the extraction protocol for different sample types from various organisms, To cover a broad concentration range, the linear or quadratic models were used and the variables 319 from X and Y axes were logarithm or squareroot transformed to fit the calibration data [43] . The 320 coefficient of determination (R 2 ) value for each metabolite was greater than 0.980 at their respective 321 concentration range, except for some metabolites such as aspartate, uracil, 2-deoxyuridine sucrose,
322
and chenodeoxycholic acid (likely due to their broad peak shapes and poor recovery at lower 323 concentration, Table S1 ).
324
Concentration precision for QC samples was calculated by measuring %CV at high, medium, of cases vs controls. This is due to high costs and also because not all internal standards are 10 of 27 commercially available. In our method, we selected 12 labeled internal standards (Table S1 ), which 352 represent chemically similar classes for optimal correction. This is because the matrix effect was 353 expected to be the same for an analyte and its labeled isotope analogue. The process efficiency 354 percentages were calculated for the metabolites without internal standards. The analyte 355 concentrations determined through the external calibration were divided with the total process 356 efficiency values to correct the concentration values of the analyte in the given biological sample.
357
Also, the repeatability of matrix effect in terms of CV was less than 25% for most of the compounds.
358
Reliable measurements are accordingly possible. 368 hours at 5 o C in the auto-sampler ( Figure 5A ).
369
For freeze and thaw cycle stability, most of the metabolites were stable even after three freeze 370 and thaw cycles, with the exception of cGMP, succinate, glutathione, and homocysteine (stability 371 below 30%, Figure 5B ). This information is particularly important for clinical studies, where samples 372 are often thawed once or twice.
373
To determine the stability of working solutions, we started evaluating the stability from 
397
observed that approximately 80% to 85% of the metabolites were always present within 25% of CV 398 values (Figure 7) . The higher %CV values for the remaining metabolites could be partially explained 399 by low abundance in human serum, low recovery, or poor chromatography; these were consistently 400 found to be below LLOQ within the 25 batches.
401
In addition, %CV values for retention times and R 2 values of calibration curves for each 402 metabolite in all the 25 batches were calculated to verify the reproducibility. Based on these results,
403
the repeatability was excellent except for a few compounds over a period of 1 year. No drifting effect 404 for the retention times (CV<4%) was observed, and excellent reproducibility was observed for R 2 405 values of calibration curves (CV<3%) (Figure 8 ). On the basis of these results, our method can be 406 considered accurate, reliable, and reproducible. To obtain reproducible and accurate data, we set up a strict quality management and electronic 418 lab notebook system. To reduce the bias from sample analysis, we always double-randomized the 419 samples (i.e., one before the sample extraction step and one before injecting into the LCMS system 420 across different phenotypes of the samples). For stabilization of response and retention time, we 421 always verified a few runs of highest calibration level 11 before injecting the experimental samples.
422
During the stabilization process, we also verified the chromatography including peak shape, 423 retention time, and response of all the metabolites. Any significant changes in the intensity, peak 424 shape, retention time, and system pressure were thoroughly investigated and corrected by resolving 425 the problems before injection of experimental samples.
426
To ensure the integrity of LCMS runs, QC samples were run at every tenth experimental sample 427 and a blank sample at every fifth run during all the metabolomics studies within a batch.
428
Furthermore, chromatography and response of QC samples (including chromatography of some 429 metabolites and IS response variation) and blank runs were always verified after completion of the 430 runs and before starting data processing. In case of any abnormality observed for particular samples, 431 those samples were reinjected or reanalyzed. Only after passing these quality checks we proceed 432 further to process the data. This included verifying the accuracy of calibration curve standards, 
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We collected concentration values (μmol/L) for our QC samples within metabolomics studies 442 conducted over a period of 5.5 years from six different lots (N=539 replicates 
447
To verify the performance of our method, we analyzed the NIST standard reference material SRM 448 1950 plasma. The correlation coefficient for 17 matched metabolites between the given reference 449 values and from our semi-quantitative method was 0.967, indicating the high performance of our 450 method ( Figure 10A ).
451
Furthermore, we verified cross-platform comparability. This was achieved by comparing 452 metabolite concentrations analyzed using our method against two completely different analytical 453 platforms (BIOCRATES AbsoluteIDQ p180 kit and NMR) in our QC samples. We obtained a high 454 correlation coefficient for matched 38 metabolites measured using BIOCRATES AbsoluteIDQ p180 455 kit and our method (R 2 =0.975) ( Figure 10B ) and for matched 22 metabolites measured using NMR 456 and our method (R 2 =0.884) ( Figure 10C ). These results demonstrate the robustness of our method. to-use data matrix for visualization and for downstream statistical analyses is a tedious and time-
481
consuming task and (most importantly) is prone to errors.
482
We have implemented a software package "Unlynx" in R statistical language. This package takes 483 the raw data produced by TargetLynx software as input and produces processed data into ready-to- 
508
The developed high-throughput targeted and semi-quantitative method was optimized for various 509 biological matrices (biofluids, tissues, cells) from different organisms. We validated the analytical 510 method according to EMA guidelines for bioanalytical methods and showed good accuracy,
511
reproducibility, selectivity, specificity, recoveries, and stability. We have also implemented a strict 512 quality management and electronic notebook system. Reproducibility was demonstrated by 513 consistent results for retention time and correlation coefficient of calibration curves, and 514 concentrations of QC samples over a period of 1 year. Reliability was shown by the excellent 515 correlation between metabolite concentrations measured using our method and the NIST reference 516 values. Moreover, robustness was shown via good cross-platform comparability between two 517 completely different analytical platforms. Furthermore, we have automated the downstream data 518 processing steps to handle sample analyses in a high-throughput manner, which is particularly 519 valuable for analyzing population cohorts and large clinical samples for metabolomics studies. We 520 have successfully applied this method in many biomedical research projects and clinical trials,
521
including epidemiological studies for biomarker discovery.
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526

